Drug Trial Radar · NCT06982963
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 4, 2025
Primary completion
Feb 28, 2027
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Forte Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
Conditions
- Celiac Disease
Interventions
FB102Biological
FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio.
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the VCIELTime frame: 78 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Royal Melbourne Hospital
Melbourne, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.